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Objective. Uterine carcinosarcoma (CS) is a rare uterine tumor with an extremely poor prognosis. In the
adjuvant setting, efﬁcacy has been shown with radiotherapy (RT), systemic chemotherapy, or both.
This is the ﬁrst report describing the efﬁcacy and toxicity of adjuvant ifosfamide or ifosfamide plus cisplatin
“sandwiched” with RT in patients with surgically staged and completely resected uterine carcinosarcoma.
Methods. Women with surgically staged CS with no gross residual disease were initially administered
ifosfamide (1.2 g/m2/day×5 days) with cisplatin (20 mg/m2/day×5 days) every 3 weeks for 3 cycles followed
by pelvic external beamRT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day)with
cisplatin (20 mg/m2/day×5 days) every 3 weeks. Similar to the GOG trial in recurrent CS (Sutton et al., 2000),
the addition of cisplatin added toxicity without additional efﬁcacy, so mid-study, the cisplatin was eliminated
from the regimen. Toxicities were recorded and disease-free survival (DFS) was calculated with Kaplan–Meier
statistical methods.Results. In total, 12 patients received ifosfamide and cisplatin and 15 patients received ifosfamide alone,
both ‘sandwiched’ with RT. The median follow up was 35.9 months (range 6–88). The 2 year DFS was similar in
both the ifosfamide/cisplatin and ifosfamide groups (log-rank p=0.16), so they were combined for analysis.
19 patients (70%) completed the protocol. As expected, stage 1 patients had a better 2-year DFS (18.75±
1.12 months; log-rank p=0.008 when compared to stages 2, 3, 4). Also, in stages 2, 3 and 4 patients, the DFS
was 15.81±1.73 months. Grade 3/4 neutropenia, anemia and thrombocytopenia occurred in 18%, 4% and 4%
of cycles, respectively.
Conclusions. Ifosfamide “sandwiched” with RT appears to be an efﬁcacious regimen for surgically staged
CS patients with no residual disease, even in patients with advanced stage. The addition of cisplatin to
the regimen added toxicity without improving efﬁcacy. Even with ifosfamide alone, the efﬁcacy of this
‘sandwich’ regimen comes with a moderate but tolerable toxicity proﬁle.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Uterine carcinosarcoma (CS) represents approximately 4% of pri-
mary uterine malignancies and 26% of uterine cancer deaths [1,2].
It is an aggressive uterine tumor with a poor prognosis and a high
recurrence rate [3]. Patterns of spread are both by hematogenous and
lymphatic dissemination which explains the pelvic and extrapelvic
sites of failure, with most patients developing extrapelvic disease [4].Albert Einstein Cancer Center
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stein).
-ND license.36% of CS patients with disease clinically conﬁned to the uterus
have nodal metastasis at the time of diagnosis and the majority
of these patients will die of metastatic disease within 2 years of the
diagnosis [5].
Even in patients with an early stage who receive adjuvant treat-
ment, pelvic failure is common. Chi et al. evaluated patients with
stage I or II CS whowere treated with surgery versus surgery followed
by whole pelvic radiation therapy. There was a trend towards fewer
pelvic recurrences in the patients who received radiation therapy
compared to those who did not (p=0.09) [6]. Other studies showed
similar statistically signiﬁcant lower rates of pelvic recurrence in pa-
tients who received radiation therapy compared to those who did
not (28% versus 48% (p=0.0002) [7] and 3% versus 55% (pb0.0001)
[8]). Although pelvic radiation has been shown to decrease the rate
of pelvic recurrence, it has not been shown to improve the overall
survival [6,7,9–14]. This ﬁnding is likely attributable to the high
27M.H. Einstein et al. / Gynecologic Oncology 124 (2012) 26–30incidence of distant metastasis known to occur at the time of CS
recurrence. In a study of CS patients who received a combination of
chemotherapy and radiation therapy in an adjuvant setting, there
was a longer median disease speciﬁc survival (pb0.001) and disease
free survival (p=0.02) [15].
Many chemotherapeutic agents that have demonstrated thera-
peutic efﬁcacy in uterine CS include adriamycin, cisplatin, ifosfamide
and paclitaxel [16–20]. The use of chemotherapy in the adjuvant set-
ting has been explored as a means of attempting to impact subclinical
extrauterine metastasis. The Gynecologic Oncology Group (GOG)
evaluated ifosfamide and cisplatin in the adjuvant setting in patients
with completely resected Stage I or II CS. At a minimum of 2 years of
follow-up, 69% were progression free and 82% remained alive [21].
However, 12 out of 23 patients recurred in the pelvis. The authors
concluded that this regimen, in the 4-day schedule, is tolerable
and the impact on progression free and overall survival was difﬁcult
to evaluate in the absence of simultaneous controls but were
better than historical controls. The high incidence of pelvic failures
suggested that a combined approach with chemotherapy and radio-
therapy should be evaluated. The results from this trial led to a ran-
domized trial of ifosfamide versus ifosfamide with cisplatin in
patients with advanced, persistent, recurrent CS with measurable dis-
ease after primary surgery [20]. This regimen was associated with sig-
niﬁcant toxicity necessitating a 20% dose reduction of ifosfamide with
the same dose of cisplatin during the course of the trial. Results from
this study identiﬁed a statistically signiﬁcant progression free interval
(p=0.02) in the ifosfamide/cisplatin group (6 months) compared to
the ifosfamide alone group (4 months). However, there was no signif-
icant difference in overall survival (p=0.07) as well as considerable
additional toxicity. In a separate GOG CS trial, chemotherapy was
compared to whole abdominal irradiation (GOG 150) [22]. After
adjusting for stage and age the estimated death rate was 29% lower
in the chemotherapy group than the WAI group. This difference was
seen despite the administration of only 3 cycles of chemotherapy.
The WAI group had more abdominal recurrences and the chemother-
apy group had more vaginal recurrences, but these were not statisti-
cally signiﬁcant.
“Sandwich” sequencing allows for treatment of systemic disease
with chemotherapy while controlling micrometastatic disease in the
pelvis with radiation therapy. In addition, this treatment allows for
the maximum therapeutic dosing for both chemotherapy and radia-
tion therapy while limiting the overall toxicity. Our group has had ex-
perience with combining sequential radiation therapy sandwiched
with paclitaxel and carboplatin chemotherapy in uterine papillary se-
rous carcinoma (UPSC) [23,24]. Patients with stages I–IV UPSC, with-
out evidence of gross residual disease received adjuvant paclitaxel/
platinum for three cycles, followed by external beam radiotherapy
(EBRT) and brachytherapy and then three more cycles of paclitaxel/
platinum. In this trial, the 3-year % survival probability for stage I/II
patients was 84% and stage III/IV patients was 50%. The vast majority
of the patients completed the prescribed protocol and most of the
toxicities were self-limiting. Grade 3 hematologic toxicities occurred
in 14% of cycles and grade 4 hematologic toxicities occurred in
13% of cycles. This regimen was considered highly efﬁcacious and
well tolerated in patients with completely resected stage I–IV UPSC.
The objective of this study was to evaluate the toxicity and efﬁcacy
of pelvic radiation “sandwiched” between cycles of ifosfamide alone
or ifosfamide and cisplatin in patients with CS, including deﬁning
patterns of recurrence.
Patients and methods
After IRB approval, eligible patients with surgically staged I–IV
CS without evidence of gross residual disease after primary surgery
were recruited from 1999 to 2009 to this registered phase II trial
(clinicaltrials.gov identiﬁer: NCT00231842). Eligible patients underwentsurgical staging comprised of total abdominal hysterectomy, bilateral
salpingo-oophorectomy, peritoneal cytology, lymph node sampling,
and omental biopsy, when clinically indicated. All eligible patients
were ≥18 years of age, had an ECOG performance status of 0 or
1, adequate hematologic function (hematocrit≥30%, WBC≥300/
mm3, platelet count≥100,000/mm3), BUN≤25 mg%, creatinine≤
2 mg%, total bilirubin≤1.5 mg/dl, aminotransferases≤2.5 times
the institutional upper limit of normal. Patients with concurrent
medical conditions limiting their life expectancy to≤3 months
or those who received prior chemotherapy and/or RT for pelvic
malignancy were excluded.
Pre-treatment evaluation and follow up
At screening, all patients had protocol-required lab testing, in-
cluding tumor markers, EKG, chest X-ray, and CT scan of the chest,
abdomen, and pelvis. In addition to a physical examination, complete
blood counts, serum electrolytes, and markers were performed prior
to each cycle of chemotherapy, after completion of chemotherapy,
every 3 months for 24 months, and then every 6 months thereafter.
Imaging was repeated after treatment and during follow-up as clini-
cally indicated. Adverse events were monitored for each cycle during
therapy and during follow-up and graded using the National Cancer
Institute Common Toxicity Criteria (CTC) version 3.0 as this trial
was initiated in 1999, prior to instituting NCI CTC v4.0.
Treatment plan
Chemotherapy
At initiation of this protocol, cisplatin at 20 mg/m2/day with
ifosfamide 1.2 g/m2/day for 5 days was administered. Similar to
what was found in the GOG trial in recurrent CS [20], in the initial
phase of this trial's two-stage design, the addition of cisplatin
added toxicity without additional efﬁcacy, so cisplatin was dropped
in the remainder of the recruited patients [25]. The ifosfamide
and RT dosing remained the same. Ifosfamide 1.2 g/m2/day was ad-
ministered parenterally for 5 days every 21 days for 3 cycles prior
to RT and 1.0 g/m2/day for 5 days every 21 days for 3 cycles after RT.
EBRT generally lasted for 5 weeks, depending on the treatment ﬁelds
and boosts, when appropriate. This was followed by brachytherapy in
all patients. To avoid chemotherapy delay, the fourth cycle of chemo-
therapy was initiated the same week as the last brachytherapy inser-
tion. Standard premedications for nausea were given. Mesna 400 mg
IV bolus followed by 1200 mg IV divided into 3 L/day×5 days for cycles
1 through 3, and 333 mg IV bolus followed by 1000 mg IV divided into
3 L/day×5 days for cycles 4 through 6 was administered sequentially
with ifosfamide.
Prior to each subsequent cycle of chemotherapy, patients were re-
quired to have recovered to an ANC ≥1500/mm3 or WBC≥3000/mm3,
platelets ≥100,000/mm3 and renal and hepatic parameters the
same as for screening. Treatment modiﬁcations for hematologic
toxicities included cycle delay until recovery with subsequent
dose reduction, in addition to G-CSF and/or erythropoietin, when
clinically appropriate. All toxicities, dose delays, and dose reduc-
tions were recorded.
Radiation
EBRT was delivered after the 3rd cycle of chemotherapy. The total
dose of EBRT was 45 Gy over 5 weeks. Patients were treated once
a day, 5 days a week, with a daily fraction of 1.8 Gy. Four-ﬁeld tech-
nique (AP-PA opposed and lateral opposed ﬁelds) was used with
a megavoltage beam of ≥ 6 MV. Extended ﬁeld radiation to the
para-aortic nodes was administered in the case of two or more posi-
tive pelvic nodes or documented para-aortic lymph node metastasis.
High dose radiation (HDR) brachytherapy was prescribed to
the proximal 2/3 of the vagina using the nucleotron microselectron
30 patients enrolled
3 did not proceed with prescribed 
regimen after registration
27 patients initiated therapy
27 patients completed the first 3 cycles          
of chemotherapy followed by RT
27 patients completed prescribed RT                
(26 had EBRT+Brachytherapy, 1 had EBRT alone)
8 did not complete last 3 cycles 
19 patients completed full prescribed therapy
of chemotherapy
Fig. 1. Treatment numbers on protocol. Toxicity analysis performed on the 27 patients
who received at least one dose of chemotherapy. Survival analysis was performed in all
patients who received the ﬁrst 3 cycles of chemotherapy followed by RT.
Table 2
Summary of grades 3 and 4 hematologic and non-hematologic toxicities (n=138 total
cycles).
Grade 3 Grade 4
Hematologic toxicities
Neutropenia 11 14
Anemia 6 0
Thrombocytopenia 6 2
Total 22 (15.9%) 16 (11.6%)
Non-hematologic toxicities
Infection (e.g. urinary) 1 0
Deep vein thrombosis 0 0
Neuropathy 1 0
Gastrointestinal 2 0
Eye disorders 1 0
Cardiovascular 1 0
Total 6 (4.3%) 0 (0%)
28 M.H. Einstein et al. / Gynecologic Oncology 124 (2012) 26–30remote after loading technique. Three fractions of 5 Gy each to 5 mm
depth from the vaginal cylinder surface was delivered. HDR was given
once a week for 3 weeks. The vaginal surface dose was calculated
at the vaginal surface lateral to the midpoint of the surface of the
cylinder.Statistical considerations
Response was evaluated using an endpoint of 2-year disease-free
survival. Disease free survival (DFS) was calculated from the date of
study entry to the date of recurrence of disease. Disease free survival
curves were constructed using the Kaplan–Meier (KM) method. For
added power, stages I and II, or early stage patients, were combined
as well as stages III and IV patients with completely resected meta-
static disease. Site(s) and date of relapse were recorded and de-
ﬁned as pelvic or distant. Pelvic sites were speciﬁed as vaginal or
other, and distant sites were speciﬁed as to their anatomic location.
Relapse was conﬁrmed by histologic or cytologic evaluation whenTable 1
Patient characteristics.
Number Percent
Race
Black 16 59
White 10 37
Other 1 4
Ethnicity
Hispanic 5 19
Non-Hispanic 22 81
FIGO stage
Total stage I 14 52
IA 2 14
IB 10 72
IC 2 14
Total stage II 3 11
IIA 0 0
IIB 3 100
Total stage III 7 26
IIIA 0 0
IIIB 0 0
IIIC 7 100
Total stage IV 3 11
IVA 0 0
IVB 3 100possible. Frequencies for toxicity and adverse events were also
recorded and tabulated.
Results
A total of 30 patients were enrolledwith three patientswithdrawing
from the protocol prior to proceedingwith therapy (see Fig. 1). Twenty-
seven subjects received the ﬁrst three cycles of chemotherapy and
RT and were included in the analysis. The initial 12 subjects received
cisplatin and ifosfamide until the protocol was amended mid-trial due
to the published mature results of the GOG trial and observed signiﬁ-
cant grades 3 and 4 toxicities with this combination [20]. The remaining
15 subjects received ifosfamide alone in a “sandwich” regimen. Of the
27 subjects, one was not a prescribed brachytherapy. Patient demo-
graphics and stage are listed in Table 1. The mean age was 65 years
(range 41–80 years). The mean BMI was 32.6 (range 21–50).
Toxicity
Out of the 27 subjects who received chemotherapy and RT, 19
(70%) completed all protocol-prescribed treatment. Four were dis-
continued from further chemotherapy after RT after being dose re-
duced to the lowest level due to grade 3/4 hematologic toxicities.
Two declined further chemotherapy after RT. Two subjects pro-
gressed during therapy. A total of 138 out of planned 162 cycles
(85%) were administered. Table 2 is a summary of the hematologic
and non-hematologic toxicities from the 27 evaluable subjects.
Grade 3/4 neutropenia, anemia and thrombocytopenia occurred
in 18%, 4% and 4% of cycles, respectively. Of note, 29/39 (74.4%) of
grade 3 and 4 hematologic toxicities occurred prior to RT. Most of
these toxicities occurred in the subjects who received cisplatin
and ifosfamide. Table 3 summarizes the number of dose reductions
and cycle delays. 7.2% of cycles required a dose reduction and 17.4%
of cycles were delayed. Three out of the 24 cycles that were delayed
were not due to treatment-related toxicities.Table 3
Number of dose reductions and delays by cycle (n=138 total cycles).
Cycle number No. of reductions No. of delays
1 0 0
2 4 6
3 3 7
4 3 3
5 0 4
6 0 4
Total 10 (7.2%) 24 (17.4%)
Fig. 2. Kaplan–Meier survival curve of early stage (stage I and II) and late stage (stage
III and IV) uterine CS patients treated with radiation “sandwiched” between three cy-
cles of cisplatin/ifosfamide or ifosfamide chemotherapy before and after RT. 2-year
DFS for early stage patients was 18.07±1.21 (mean±standard error) months and
for advanced stage patients was 15.72±1.79 months.
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In the 27 evaluable subjects, the median follow up time was
34.2 months (range 6.4–88months). For 2-year DFS the median
follow-up time was 19.6 months (range 6.4–24 months). Two subjects
were lost to follow up after at least 14 months from initiation of treat-
ment. The 2-year DFS was similar in both the cisplatin/ifosfamide
and the ifosfamide groups (p=0.16) so both groups were combined
for analysis. During the study and post-treatment follow-up period,
10/27 (37%) patients recurred, 3/17 (17.6%) of stage I/II and 7/10
(70%) of stage III/IV patients. Therewere no preferential patterns of fail-
ure. Of the 10 subjects that recurred, 6 had a distant recurrence (4 in the
lung, and 2 in the abdomen), and 4 recurred in the pelvis (2 were nodal
recurrences). Fig. 2 shows the survival curve stratiﬁed by early stage
(stage I/II) and advanced stage (stage III/IV) patients. The 2-year DFS
time for early stage patients was 18.07±1.21 (mean±standard
error) months and for advanced stage patients was 15.72±
1.79 months. The survival probability at 2 years was 80.8% in stage I/II
and 30.3% in stage III/IV patients.
Discussion
There still is no clear consensus on the best adjuvant therapy
for patients with uterine CS, where survival is exceedingly poor.
While combined chemotherapy regimens which include cisplatin,
ifosfamide, and paclitaxel have been found to be efﬁcacious in a treat-
ment setting for uterine CS [17–20], there are few prospective studies
where therapy has been used in an adjuvant setting. This study
supports that combination chemotherapy and radiotherapy in a
‘sandwich’ fashion has efﬁcacy in the adjuvant treatment of uterine
CS. Toxicity with single agent ifosfamide was moderate and mostly
self-limiting. However, due to the need for inpatient administration
because of the concomitant parenteral Mesna as well as the overall
toxicity proﬁle of this combined therapy, other chemotherapeutic
agents, such as paclitaxel and carboplatin “sandwich” therapies
should be explored. Our group has been using paclitaxel and carbo-
platin “sandwiched” with RT in a similar rare uterine cancer, uterine
papillary serous carcinoma [23,24]. This sequence was shown to be
both efﬁcacious and tolerable in UPSC.
Combined paclitaxel and ifosfamide in recurrent or persistent
uterine CS was evaluated in GOG 161 which showed improved overall
survival, 14 months versus 8 months with ifosfamide alone [26]. The
response rate was 45% compared to 29% with ifosfamide alone butthe toxicity was worse when combined with paclitaxel. In our
study, we found the same additional toxicity when adding cisplatin
to ifosfamide.
Data from our prospective trial support the beneﬁt of combined
chemotherapy and RT for completely resected CS in the adjuvant
setting. The 2-year DFS was 18.07±1.21 months for stage I/II patients
and 15.72±1.79 months for stage III/IV patients. The most common
toxicities were mostly self-limiting grades 3 and 4 hematologic
toxicities, the majority of which occurred prior to RT. RT did
not appear to add more post-RT hematologic toxicity, despite the
added marrow exposure. Similar to historical data, early stage
(stage I/II) patients had better progression free survival compared
to advanced stage (stage III/IV) patients.
Although our study was a prospective trial, there are limitations.
There is potential for bias that is attributed to any single institution
trial. Due to the relative paucity of CS, our sample size is small, but
sizable considering a single institution study. Our favorable ﬁndings
warrant a larger studywith a “sandwich” regimenwith chemotherapy
that is easier to use with a better toxicity proﬁle.Conﬂict of interest statement
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